NASDAQ: JANJanone Inc Stock
$3.66-0.16 (-4.19%)
Updated Apr 17, 2024
JAN Price
$3.66
Fair Value Price
-$0.18
Market Cap
$31.45M
52 Week Low
$0.22
52 Week High
$4.08
P/E
-1.88x
P/B
-9.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.2
Operating Cash Flow
$1M
Beta
1.05
Next Earnings
May 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A
JAN Overview
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JAN ($3.66) is overvalued by 2,188.25% relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JAN ($3.66) is not significantly undervalued (2,188.25%) relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JAN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more JAN due diligence checks available for Premium users.
Be the first to know about important JAN news, forecast changes, insider trades & much more!
JAN News
Valuation
JAN fair value
Fair Value of JAN stock based on Discounted Cash Flow (DCF)
Price
$3.66
Fair Value
-$0.18
Undervalued by
2,188.25%
JAN ($3.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JAN ($3.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
JAN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JAN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.88x
Industry
16.17x
Market
41.64x
JAN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.51x
Industry
5.8x
JAN's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.8M
Profit Margin
0%
JAN's Earnings (EBIT) of -$8.24M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.5M
Liabilities
$7.3M
Debt to equity
-2.2
JAN's short-term liabilities ($5.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JAN's long-term liabilities ($1.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JAN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$409.0k
Investing
$1.0k
Financing
$0.0
JAN's operating cash flow ($1.46M)... subscribe to Premium to read more.
Debt Coverage Financials
JAN vs Waste Management Stocks
Janone Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.